Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Boehringer’s Japan Pharma Sales on Course for Recovery; Jardiance, Spiolto Upbeat
June 7, 2019
- Astellas Ties Up with Microsoft to Develop Tool Using “Mixed Reality” to Improve Medication Adherence
June 7, 2019
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
- Merck SVP Roy Baynes Recounts Keytruda Development, Says We Followed Science
June 6, 2019
- Japan Fair Trade Watchdog Issues Cease and Desist and Surcharge Payment Orders to Koa Isei for Price Fixing
June 6, 2019
- Otsuka Chemical Acquires Cefixime-Related Business from Astellas
June 6, 2019
- Fujifilm Develops Continuous Production System for Biologics, Set to Begin Contract Manufacturing in 2020
June 6, 2019
- Fujifilm Invests 200 Million Yen in Cell Therapy Startup
June 5, 2019
- Xofluza Hits Goal of Preventing Flu Onset in Japan PIII: Shionogi
June 5, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
- Amazon Web Services to Enhance Services for Healthcare Industry in Japan
June 5, 2019
- Takeda’s Takhzyro Reduces HAE Attacks in Initial Phase of Treatment
June 5, 2019
- No Japanese Enrolled, but AstraZeneca to Discuss Lynparza’s Pancreatic Cancer Data with PMDA: Oncology Chief
June 4, 2019
- Alecensa Slashes Progression Risk by 63% vs. Xalkori in Frontline NSCLC
June 4, 2019
- Lumicef Now in Japan PIII for Systemic Sclerosis: Kyowa Kirin
June 4, 2019
- Alecensa Filed in Japan for Rare Lymphoma: Chugai
June 4, 2019
- Rakuten Medical’s Photoimmunotherapy Demonstrates Favorable Tolerability in PIIa
June 4, 2019
- ASKA to Transfer Menoaid Hot Flash Drug to Hisamitsu
June 4, 2019
- Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
June 4, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…